An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
NCT04662931
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
Sickle Cell Disease (SCD)
Interventions
DRUG:
crizanlizumab
Sponsor
Novartis Pharmaceuticals